Type 2 diabetes
Conditions
Interventions
Baseline metformin combined with DPP-4i group:metformin combined with acarbose group (metformin 500mg tid, acarbose 100mg tid) or metformin combined with sitagliptin group (metformin 500mg tid, sitagl
Baseline metformin combined with AGI group:metformin combined with acarbose group (metformin 500mg tid, acarbose 100mg tid) or metformin combined with sitagliptin group (metformin 500mg tid, sitaglipt
Sponsors
Department of Endocrinology and Metabolism, Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with type 2 diabetes (WHO, 1999 diagnosis criteria); 2. Patients now receiving metformin combined with acarbose or metformin combined with sitagliptin treatment for at least 1 month; 3. Aged 18-65 years, male or female; 4. Level of HbA1c from 6% to 9%; 5. 19 <= BMI <= 35 kg/m2; 6. Signing the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with repetitive onset of severe hypoglycemia or asymptomatic hypoglycemia; 2. Suspiciously or confirmed allergic to hypoglycemic agents used in this trial; 3. Women in pregnancy or in lactation period, or with intends of pregnancy during the trial period; 4. Patients with abnormal hepatic function, defined as ALT or AST exceeding 2.5 times of normal upper limit; 5. Patients with systematic diseases, including severe heart disease, tumor, tuberculosis, acute infectious disease and so on; 6. Patients with systematically endocrine diseases (hypothyroidism, hyperthyroidism, hypercortisolism); 7. Hypertension without ideal control, defined as SBP >= 180mmHg and/or DBP >= 100mmHg; 8. Diabetic ketoacidosis or hyperosmotic non-ketotic hyperglycemic coma; 9. Accompanying systematic diseases which may influence the change of blood glucose and body weight; 10. Patients with abnormal renal function, defined as Cr >= 1.5 mg/dl (male) ?Cr >= 1.4 mg/dl (female) 11. Patients with mental diseases or problem of drug abuse; 12. Patients with intends to conduct X-ray, CT and MRI examination during the 14-day trial period with FGM; 13. Patients currently participating in other drug clinical trials; 14. Patients evaluated as not suitable for this clinical trial by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flash continuous glucose monitoring data; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate;blood pressure;Respiration rate;Height;Weight;BMI;blood routine;urine routine;urine pregnancy test;Hepatic function (ALT, AST);Renal function (CRE, calculated eGFR);Fasting blood glucose;HbA1c;Glycated albumin;Fasting insulin;Fasting C-peptide;Serum cytokine testing;12-lead electrocardiogram; | — |
Countries
China
Contacts
Public ContactLinong Ji
Department of Endocrinology and Metabolism, Peking University People's Hospital
Outcome results
None listed